Next Article in Journal
Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target
Next Article in Special Issue
Suppressive Effect of the α-Amylase Inhibitor Albumin from Buckwheat (Fagopyrum esculentum Moench) on Postprandial Hyperglycaemia
Previous Article in Journal
What is the Validity of Questionnaires Assessing Fruit and Vegetable Consumption in Children when Compared with Blood Biomarkers? A Meta-Analysis
Previous Article in Special Issue
A Pilot Study for the Detection of Cyclic Prolyl-Hydroxyproline (Pro-Hyp) in Human Blood after Ingestion of Collagen Hydrolysate
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 10
Issue 10
10.3390/nu10101397
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Purification and Identification of Angiotensin I-Converting Enzyme Inhibitory Peptides and the Antihypertensive Effect of Chlorella sorokiniana Protein Hydrolysates

by
Yu-Hsin Lin
1,
Guan-Wen Chen
2,*,
Chin Hsi Yeh
3,
Helena Song
3 and
Jenn-Shou Tsai
2
1
Department of Food Technology and Marketing, Taipei University of Marine Technology, No. 212, Section 9, Yan Ping North Road, Taipei 111, Taiwan
2
Department of Food Science, National Taiwan Ocean University, No. 2 Pei-Ning Road, Keelung 202, Taiwan
3
Taiwan Chlorella Manufacturing Co., Ltd., 5 F, No. 71, Section 2, Nan-King East Road, Taipei 104, Taiwan
*
Author to whom correspondence should be addressed.
Nutrients 2018, 10(10), 1397; https://doi.org/10.3390/nu10101397
Submission received: 26 August 2018 / Revised: 13 September 2018 / Accepted: 28 September 2018 / Published: 1 October 2018
(This article belongs to the Special Issue Impact of Bioactive Peptides on Human Health)
Browse Figures
Versions Notes

Abstract

:
Hot water was used to obtain Chlorella sorokiniana hot water extract (HWE). Subsequently, this byproduct was freeze-dried, hydrolysed at 50 °C using Protease N to obtain C. sorokiniana protein hydrolysates (PN-1), and then digested with a gastrointestinal enzyme (PN-1G). The inhibitory effects of the HWE and hydrolysates against angiotensin I-converting enzyme (ACE) were investigated. The soluble protein and peptide contents were 379.9 and 179.7 mg/g, respectively, for HWE and 574.8 and 332.8 mg/g, respectively, for PN-1. The IC50 values of the HWE, PN-1, and PN-1G on ACE were 1.070, 0.035, and 0.044 mg/mL, respectively. PN-1G was separated into seven fractions through size exclusion chromatography. The sixth fraction of the hydrolysate had a molecular weight between 270 and 340 Da, and the lowest IC50 value on ACE was 0.015 mg/mL. The amino acid sequences of the ACE-inhibitory peptides were Trp-Val, Val-Trp, Ile-Trp, and Leu-Trp, of which the IC50 values were 307.61, 0.58, 0.50, and 1.11 µΜ, respectively. Systolic blood pressure and diastolic blood pressure were reduced 20 and 21 mm Hg, respectively, in spontaneously hypertensive rats after 6 h of oral administration with a dose of 171.4 mg PN-1 powder/kg body weight.

1. Introduction

Hypertension has been identified as a cardiovascular risk factor and is often called a “silent killer” because people with hypertension can remain asymptomatic for years [1]. The prevalence of hypertension has reached epidemic levels, affecting 15 to 20% of adults worldwide [2]. One therapeutic approach to treating hypertension is inhibition of angiotensin I-converting enzyme (ACE) using synthetic drugs. ACE plays a key physiological role in blood pressure regulation of the renin–angiotensin system. ACE inhibitors such as captopril and enalapril [3,4] have been used as antihypertensive drugs [5,6]. However, such therapy can produce adverse effects, including coughing, loss of taste, angioedema, and skin rashes [7]. Hence, a trend has formed towards the development of natural ACE inhibitors.
Peptides are the most commonly studied natural compounds that inhibit ACE activity [8,9,10,11]. Therefore, to obtain ACE-inhibitory peptides, numerous studies have focused on the hydrolysis of food protein-based matrices such as fermented milk [12,13,14], shellfish [15,16], chicken [17], mushrooms [18], fish [19,20], and the following types of algae Undaria pinnatifida, Chlorella vulgaris, and Spirulina platensis [1,16,21,22,23]. Among these protein sources, protein from algae has received particular attention because of its potentially beneficial effects related to hypertension [24,25,26]. In addition, reports have noted that algae protein hydrolysate decreases blood pressure in spontaneously hypertensive rats (SHRs), which suggests that certain peptides possess potent antihypertensive effects comparable with those of pharmaceutical drugs [27,28,29,30]. After performing hydrolysis on Porphyra yezoensis by using pepsin, one study separated the primary ACE-inhibitory peptides Ile-Tyr, Ala-Lys-Tyr-Ser-Tyr, Leu-Arg-Tyr, and Met-Lys-Tyr [27]. The IC50 values of these peptides were 2.69, 1.52, 5.06, and 7.26 μM, respectively. After 1 h following oral administration of this hydrolysate to SHRs at a dose of 200 mg/kg body weight (BW), the SHRs’ systolic blood pressure (SBP) was reduced by 53.0 mm Hg. Through the hydrolysis of C. vulgaris using Alcalase, an ACE-inhibitory peptide with an amino acid sequence of Ile-Gln-Pro and IC50 value of 5.77 μM was separated [30]. This tripeptide was then administered to SHRs via tube feeding. After 2 to 4 h, this tripeptide achieved the same blood pressure-lowering effect as captopril at the same dose [30]. In the C. vulgaris hydrolysate obtained through hydrolysis using pepsin, the sequence of the primary ACE-inhibitory peptide was Phe–Ala–Leu, and its IC50 value was 26.3 μM. This peptide fraction was administered to SHRs at a dose of 200 mg/kg BW. After 1 h following oral administration, the SBP of the SHRs was reduced by 49.9 mm Hg [21]. However, few studies have examined ACE-inhibitory peptides derived from protein hydrolysate of green algae. A review identified three studies [1,21,23] on ACE-inhibitory peptides from Chlorella sp; however, information regarding the ACE-inhibitory activity and antihypertensive effect of protein hydrolysate from C. sorokiniana is limited. ACE-inhibitory peptides prepared from C. sorokiniana are of great interest because of the abundance of proteins in this alga.
C. sorokiniana is a microalga within the green alga grouping and an edible single-cell microalga that does not cause side effects when consumed [1]. Green algae are composed of approximately 60% protein and have carbohydrate and lipid contents of 12 to 17% and 14 to 22%, respectively [31]. Hot water extracts (HWEs) of green algae are often used in dietary supplements and are commercially available. After hot water extraction, a substantial amount of green algae residue containing approximately 50% protein remains. This byproduct is a comparatively cheap protein source compared with most bioactive peptides deriving from expensive animal and plant proteins [1]. Algae protein waste is often used only as a protein source in animal feed. To better utilise C. sorokiniana protein waste, after hot water extraction, such waste should be initially freeze-dried and subsequently hydrolysed by using commercial enzymes, to produce some bioactive peptide substances. In this study, the inhibitory effects of C. sorokiniana protein waste on ACE were measured to compare the efficacy of the extracts and hydrolysates. The stability of the hydrolysates’ ACE-inhibitory activity was examined by simulating gastrointestinal digestion. Furthermore, the ACE-inhibitory peptides of the hydrolysates following digestion by gastrointestinal protease were fractionated using gel filtration to determine their molecular weights (MWs), purified by reverse-phase high-performance liquid chromatography (RP-HPLC), and subjected to amino acid sequence analysis. The antihypertensive effect of the hydrolysates on SHRs was investigated through short-term oral administration.

2. Materials and Methods

2.1. Materials

C. sorokiniana was supplied by an aquaculture farm (Taiwan Chlorella Manufacturing Co., Taipei, Taiwan). Protamex with a nominal activity level of 1.5 AU/g was supplied by Novozymes (Novo Nordisk A/S Co., Bagsværd, Denmark). Protease N with a nominal activity level of 150,000 U/g was supplied by Amano Pharmaceutical Co. (Yokohama, Kanagawa, Japan). Pepsin, pancreatin, hippuryl-l-histidyl-l-leucine (HHL), ACE of rabbit lung, and other chemicals of analytical grade were obtained from Sigma Chemical Co. (St. Louis, MO, USA).

2.2. Preparation of Hot Water Extract and Hydrolysate of C. sorokiniana

Whole C. sorokiniana was mixed with tap water at a 1:10 (w/w) ratio and incubated at 90 °C for 30 min to simulate the commercial procedure. The resulting liquid was filtered through No. 2 filter paper (Toyo Roshi Kaisha, Tokyo, Japan), and lyophilised to become the HWE of C. sorokiniana. The residues were then collected and further lyophilised to a powder. Next, this powder was homogenised with deionised water at a ratio of 1:10 for 2 min and boiled for 10 min to produce C. sorokiniana homogenate. After this mixture had cooled to ambient temperature, the enzyme (Protamex or Protease N) was added to the substrate at ratios of 1:100 (w/w) and 2:100 (w/w). This reaction mixture was incubated at 50 °C for 5 h, and the protease was subsequently inactivated by incubation at 98 °C for 10 min. Centrifugation at 12,000× g (SCR 20BA, Hitachi Co. Ltd., Tokyo, Japan) for 20 min then produced a supernatant that was filtered through No. 2 filter paper; finally, the filtrate was collected and lyophilised to powder form in preparation for analysis or orally administered to SHRs via gastric intubation.

2.3. Chemical Analyses

The soluble protein contents of the HWE and hydrolysate were measured using the Folin–Lowry method [32,33] with bovine serum albumin as the standard. A total of 1 mL of an alkaline copper reagent was added to each sample, followed by 3 mL of Folin–Ciocalteu reagent (diluted 10-fold with deionised water) (Merck, KGaA, Darmstadt, Germany). Subsequently, the mixture was incubated at ambient temperature for 30 min and determined for the absorbance of the reaction mixture at 540 nm by using a spectrophotometer (Model UV-160A, Shimadzu, Kyoto, Japan).

2.4. Measurement of Peptide Content

The peptide content of the samples was measured by an ortho-phthaldialdehyde reagent with dipeptide (Leu-Gly) (Sigma, St. Louis, MO, USA) as a standard according to a modification of the method of Church et al. [34]. Prior to the measurement, the sample solution (30 mg/mL) was filtered through a 0.22-μm membrane, and the filtrate was passed through an ultrafiltration membrane (Millipore, Bedford, MA, USA) with an MW cut-off (MWCO) of 5000 Da. Then, 50 μL of the resulting permeate was mixed with 2 mL of the ortho-phthaldialdehyde reagent and incubated at ambient temperature for 2 min. The absorbance of the reaction mixture was subsequently determined using a spectrophotometer (UV-160A, Shimadzu, Taipei, Taiwan), which measured it as 340 nm.

2.5. In Vitro Assay for ACE-Inhibitory Activity

ACE-inhibitory activity was evaluated through RP-HPLC and assayed using the modified spectrophotometric method described by Cushman and Cheung [35] and Wu and Ding [36]. In brief, 15 mM HHL was dissolved in 100 mM Na-borate buffer (pH 8.3) supplemented with 300 mM NaCl. Rabbit lung ACE was dissolved in the same buffer at a concentration of 53.2 mU/mL. A mixture containing 75 μL of ACE solution and 75 μL of the sample with a 5000-Da MWCO membrane (Millipore, Burlington, MA, USA) was incubated at 37 °C for 10 min, to which was added 75 μL of HHL solution, and the mixture was incubated for a further 30 min. The reaction was halted by addition of 250 μL of 1 N hydrochloric acid, and 10 μL of this solution was injected directly into a Luna C18 analytical column (4.6 × 250 mm2, particle size: 5 μm; Phenomenex, Torrance, CA, USA) to separate the substrate HHL and product hippuric acid (HA) liberated through hydrolysis of HHL. The column was eluted with a mobile phase of 0.1% trifluoroacetic acid in methanol and water (50/50, v/v) at a constant flow rate of 0.8 mL/min using a pump (model L-7100, Hitachi, Tokyo, Japan) and monitored at 228 nm using an ultraviolet (UV) spectrophotometer (UV-VIS detector 118, Gilson Medical Electronics, Villiers-le-Bel, France). Finally, inhibition activity was calculated using the following formula.
Inhibition activity (%) = [(Ec − Es)/(Ec − Eb)] × 100
where Ec is the absorbance with addition of the buffer instead of the test sample (control), Es is the absorbance when the sample was added to the reaction mixture (sample), and Eb is the absorbance when the stop solution was added before the reaction occurred (blank). The IC50 value was defined as the concentration of peptide in milligrams per millilitre required to reduce 50% of the absorbance peak height of the HA (50% inhibition of ACE), which was determined through regression analysis of ACE inhibition (%) versus the log 10 (peptide concentration, mg/mL) curve and constructed using at least six separate analyses to calculate the concentration. Captopril (positive control) exhibited the highest significant ACE-inhibitory activity (IC50 value = 0.0069 μM). All data presented in this paper are the average of three repeats or mean ± standard deviation (SD).

2.6. In Vitro Gastrointestinal Digestion

Digestion was simulated in vitro with slight modifications to previously published methods [36]. A 3.5% PN-1 (w/v) (control group) was redissolved in 0.1 M KCl-HCl (pH 2.0) buffer with pepsin at an enzyme-to-protein ratio of 1:25 (w/w) for 4 h at 37 °C, after which the reaction was halted through heating in a boiling water bath for 10 min. Subsequently, the reaction mixture was neutralised to pH 7.0 with 2M NaOH solution. The neutralised suspension (50 mL) was centrifuged (10,000× g, 30 min) to produce a supernatant that was subsequently used to determine ACE-inhibitory activity. The remaining neutralised suspension was then digested with pancreatin (E:S = 1:25 (w/w)) at 37 °C for 4 h. The enzyme was inactivated by boiling water for 10 min and then centrifuged at 10,000× g for 30 min. The resulting supernatant was used to determine ACE-inhibitory activity. In addition, this supernatant was collected and lyophilised to powder form in preparation for analyses.

2.7. Size Exclusion Chromatography

The lyophilised hydrolysate that exhibited the highest ACE-inhibitory activity was fractionated through gel filtration chromatography on a Sephadex G-15 column (1.6 × 90 cm2; Amersham Pharmacia Biotech AB, Uppsala, Sweden) and then equilibrated with deionised water. The hydrolysate powder (200 mg) was then dissolved in 10 mL of deionised water; the resulting solution was passed through the 5000-Da MWCO membrane, and the filtrate of 2 mL was directly injected into the column and eluted with deionised water at a constant flow rate of 0.5 mL/min. Resultant fractions of 5 mL each were collected, and the absorbance of each fraction at 280 nm was determined. Notably, the MW standards for calibration of gel filtration were bacitracin (MW 1422 Da), penta-l-phenylalanine (MW 753.9 Da), and tryptophan (MW 204.2 Da).

2.8. Purification of ACE-Inhibitory Peptide

Purification of ACE-inhibitory peptide from protein hydrolysate was performed by following the method described by Chen et al. with minor modifications [12]. The aforementioned fraction from gel filtration with the highest inhibition of ACE was collected, lyophilised, and further purified through RP-HPLC (L-7100, Hitachi) using an analytical C18 column (Synergi 4 μ Hydro-RP 80A, 10 × 250 mm2; particle size: 4 μm; Phenomenex, Torrance, CA, USA). Solution A was deionised water containing 0.1% trifluoroacetic acid, and solvent B was acetonitrile solution. Elution was performed at ambient temperature with a linear gradient from 0% to 40% of solvent B within 120 min. The flow rate was set at 1.5 mL/min, and the sample load volume was 500 μL. The absorbance of the resultant eluate was monitored at 220 nm by using a UV spectrophotometer (UV-VIS detector 118, Gilson Medical Electronics, Middleton, WI, USA) connected to a data station (715 system controller, Gilson Medical Electronics). The peaks were collected via repeated chromatography, and then each peak purity was confirmed as a single component by using a reversed-phase C12 column (Joupiter 4 μm Proteo 90 A, 250 × 4.6 mm2, Phenomenex) with linear gradients from 0 to 40% acetonitrile solution within 120 min at a flow rate of 1.5 mL at ambient temperature. The absorbance of elution was monitored at 220 nm. Finally, the peaks exhibiting the highest ACE-inhibitory activity were collected and lyophilised, and their amino acid sequences were identified.

2.9. Sequence Analysis

The sequence of the peptide was identified by following the method described by Lin et al. with slight modifications [20]. Samples were first prepared prior to sequencing analysis. The PN-1G concentration was increased from 20 to 100 mg/mL and separated by gel filtration chromatography. The fraction F was collected through triplicate chromatography. Three combined collections were lyophilised and then dissolved in 0.5 mL of deionised water. The resulting solution was further purified on an RP-HPLC column (ODS C18) using the aforementioned method. Each peak was collected five times through repeated chromatography and then confirmed as a single component with an RP-HPLC C12 column using the aforementioned method. The five collected mixtures were then lyophilised, and their ACE-inhibitory activities and amino acid sequences were analysed. Next, the sequences of ACE-inhibitory peptides were identified through automated Edman degradation using a Procise 492 protein sequencer (Perkin-Elmer Co. Ltd., Applied Biosystem Inc., Foster City, CA, USA) [20]. Finally, the amino acid sequences of identified peptides were synthesised through solid-phase peptide synthesis. Synthetic peptides were used as the standard for qualitative analysis of these peptides in algae protein hydrolysates, followed by use of an RP-HPLC C12 column through the aforementioned method. The amino acid sequence alignment of C. sorokiniana proteins (e.g., succinate dehydrogenase (ubiquinone) iron-sulphur subunit, mitochondrial [accession number: A0A2P6TTG2]; photosystem II protein D [accession number: W8SIR2]; and ribokinase [accession number: A0A2P6TU56]) was performed using the UniProt database [37]. To confirm identical sequences, the pairwise sequence alignment tools available [38].

2.10. Animals and In Vivo Measurement of Blood Pressure

All animal experiments were executed in accord with the guidelines for the Care and Use of Laboratory Animals under a protocol approved by the Institutional Animal Care and Use Committee of National Taiwan Ocean University, Keelung, Taiwan. The approval number for the ethical clearance was 96,023. Eighteen male SHRs aged 7 weeks were purchased from the National Laboratory Animal Center, Taipei, Taiwan. The SHRs were housed in cages with a maintained light–dark cycle of 12 h. The constant temperature and humidity in the animal room were controlled at 23 ± 1 °C and 55% ± 5%, respectively. The SHRs were fed a standard laboratory diet (Rodent Laboratory Chow Diet 5001, PMI Nutrition International, Brentwood, MO, USA). Tap water was freely available to the rats for eight weeks before the beginning of the experimental period. At the age of 15 weeks, the SHRs (body weight = 350 ± 5 g, SBP = 173.0 ± 4.2 mm Hg, diastolic blood pressure (DBP) = 150.0 ± 3.7 mm Hg) were divided into two experimental groups (both n = 6) that were respectively administered PN-1 dissolved in 2 mL of saline by gastric intubation at doses of 30 and 60 mg of powder/rat BW (350 g, equivalent to 85.7 and 171.4 mg of powder/kg BW or 10 and 20 mg peptide/rat BW). Equal volumes of saline were given to the control group (n = 6) during the trial. The SBP and DBP of each SHR were measured at 2, 4, 6, 8, and 24 h after oral administration. Each rat was placed in a thermostatic box at 45 °C for 5 min to determine the SBP, DBP, and heart rate by using the tail-cuff method (BP-98, Softron, Tokyo, Japan). The results are shown as means and SDs.

2.11. Statistical Analysis

Changes in blood pressures are expressed as the difference in SBP and DBP before and after oral administration of PN-1 containing 30 and 60 mg of peptide/rat BW. Data are given as mean ± SD except for the yield of C. sorokiniana protein hydrolysates, size exclusion chromatography, and RP-HPLC chromatography, which are reported as the averages of three samples. An analysis of variance for the results of the aforementioned experiments was conducted using the SAS [39] general linear model procedure. Multiple mean comparisons were performed using Duncan’s multiple range test.

3. Results and Discussion

3.1. Soluble Protein Content, Peptide Content, Yield, and IC50

The residue of the HWE of C. sorokiniana underwent hydrolysis using Protamex and Protease N. Table 1 presents the effects of the hydrolysis on soluble protein, peptide content, yield, and ACE-inhibitory activity. The results revealed that compared with HWE, hydrolysates subjected to protease hydrolysis had higher yields and higher soluble protein and peptide content. Moreover, as the amount of protease added increased, so did the protein and peptide compositions. Specifically, the hydrolysates of Protease N (PN-1 and PN-2) had higher yields and higher soluble protein and peptide contents than did those of Protamex hydrolysates (PX-1 and PX-2). PN-1 had yields and soluble protein and peptide contents that were 1.5, 1.4, and 1.3 times that of PX-1, respectively, and those of PN-2 were 1.1, 1.2, and 1.1 times that of PX-2, respectively. The soluble protein contents of PN-1 and PN-2 were 1.5 and 1.6 times that of HWE, respectively; the peptide contents of PN-1 and PN-2 were 1.8 and 1.9 times that of HWE, respectively; and the yields of PN-1 and PN-2 were 7.0 and 7.8 times that of HWE, respectively (Table 1). The IC50 of HWE was 1.070 mg/mL. However, of all the hydrolysates derived from the C. sorokiniana residues, PN-1 had the most satisfactory ACE-inhibitory effect, and its IC50 value was 0.035 mg/mL (Table 1).
These results show that use of PN-1 in the mass processing of plants can reduce the amount of enzymes used in this process, thereby lowering cost. Therefore, this study focused on PN-1.

3.2. In Vitro Stability of C. sorokiniana–Derived ACE-Inhibitory Peptides

In vitro gastric digestion provides a practical and easy process to imitate oral administration of bioactive peptides. The ACE-inhibitory activity of C. sorokiniana-derived peptides decreased markedly after increasing IC50 from 0.035 to 0.044 mg peptide/mL through hydrolysis with pepsin and pancreatin, which simulated stomach and small intestine digestion (Table 2). This may be because (1) after the rehydrolysis of pepsin and pancreatin the ACE-inhibitory peptides also underwent rehydrolysis or (2) the proportion of ACE-inhibitory peptides decreased, leading to an increase of IC50 and an inferior ACE-inhibitory effect. The main ACE-inhibitory peptide obtained from manchego cheese through purification was αS2-CN f 205-208 (VRYL). Subsequently, this peptide underwent hydrolysis with digestive enzymes (i.e., pepsin, chymotrypsin, and trypsin), after which its IC50 value increased from 0.009 to 0.03 mg/mL. The inhibitory capacity of ACE decreased because the hydrophobic amino acid leucine at the carboxy terminal of VRYL underwent hydrolysis and produced VRY [40]. This outcome showed that ACE-inhibitory peptides are released through hydrolysis by proteolytic enzymes and can survive or maintain their active form even following gastrointestinal digestion.

3.3. Isolation and Purification of ACE-Inhibitory Peptide

In this study, the ACE inhibitory effect of PN-1 exhibited a decreasing trend (its IC50 value increased from 0.035 to 0.044 mg/mL) after it was enzymatically hydrolysed in the stomach and intestines. This result indicates that enzymes in the stomach and intestine can rehydrolyse ACE inhibitory active peptide sequences in PN-1 mixtures. To purify and identify possible active peptides generated by PN-1 in the stomach and intestines of SHRs, we selected PN-1G to perform purification and identification. The MW distribution of the ACE-inhibitory peptides in PN-1 after digestion by gastrointestinal proteases (PN-1G) was fractionated by size exclusion chromatography on a Sephadex G-15 column. Seven fractions were separated and designated as A–G (Figure 1), and their MWs ranged from 1400 to 200 Da. The peptide concentrations of fractions A–G were 0.210, 0.027, 0.025, 0.064, 0.057, 0.034, and 0.053 mg/mL, respectively (Table 3). Although fraction A had the highest ACE-inhibitory proportion and peptide content, the data for effective ACE inhibition (inhibitory efficiency ratio (IER) = inhibition (%)/peptide concentration (mg/mL)) indicated that fractions B, C, E, and F exhibited superior inhibition than did the other peaks, ranging between 1130% and 2230% per mg/mL. The IC50 value for ACE was further analysed; the results revealed that of all the fractions, fraction F was the most effective at inhibiting ACE activity, and its IC50 value was 0.0150 mg/mL (Table 3). Compared with PN-1 after digestion by gastrointestinal proteases, the ACE inhibition capacity of fraction F markedly improved, with its IC50 value being reduced to approximately one-third of that of PN-1G. The MW of fraction F was 270 to 340 Da, indicating that it was a di- or tripeptide. The highest ACE-inhibitory effect was similar to that of the potent inhibitory tripeptides found in C. vulgaris, S. platensis, and U. pinnatifida [21,30,41].
The most active peptide of fraction F was further purified on an RP-HPLC column (ODS C18). The elution profiles of the peptides are shown in Figure 2. Ten major peaks were observed and labelled according to the eluted order of 1 to 10. These 10 peaks were collected separately through repeated chromatography, and each peak was confirmed as a single component by an RP-HPLC C12 column with the same gradients comprising 0 to 40% acetonitrile solution. In addition, the IER values of the F1–F10 peaks were measured. The results revealed that the F7, F8, F9, and F10 peaks had relatively strong ACE-inhibitory effects, with IERs of 5425%, 8613%, 9510%, and 8770% per mg/mL, respectively (Table 4). Finally, peaks F7, F8, F9, and F10 were collected separately, lyophilised, and further analysed to determine their amino acid sequences.

3.4. Amino Acid Sequences and ACE-Inhibitory Activity

The amino acid sequences and IC50 values for the peptides from peaks F7, F8, F9, and F10 are shown in Table 5. The peptide sequences of the F7, F8, F9, and F10 peaks were Trp–Val, Val–Trp, Ile–Trp, and Leu–Trp, respectively, and the IC50 values of the F7, F8, F9, and F10 peaks were 307.61, 0.58, 0.50, and 1.11 μM, respectively (equivalent to 0.0933, 0.00018, 0.00016, and 0.00035 mg/mL, respectively). These isolates were identified as a part of the amino acid sequence of succinate dehydrogenase (ubiquinone) iron-sulphur subunit, mitochondrial residues 2031–2032, 552–553, 2736–2737, and 3738–3739, respectively [37]. Sekiya et al. [42] reported that food-derived peptides with IC50 values between 100 and 500 μM have potential as antihypertensive agents. Compared with the C. sorokiniana protein hydrolysate (0.044 mg/mL), which did not undergo purification, the IC50 values of Val-Trp, Ile-Trp, and Leu-Trp were approximately 244, 275, and 126 times lower, respectively. In addition, research on ACE-inhibitory peptides has identified Val–Trp, Ile–Trp, and Leu–Trp in various protein hydrolysates such as the hydrolysates of wakame (U. pinnatifida), fish sauce, sake lees, dried bonito, ovalbumin, and salmon; the IC50 values ranged between 0.48 and 31.3 μM [43,44,45,46], 0.7 and 4.7 μM [44,47,48,49], and 6.76 and 50.12 μM [47,50,51], all of which were similar to the IC50 value of the purified peptide from PN-1G. The IC50 value for Trp-Val prepared in this study through purification was lower than the value obtained by Ono et al. (500.5 μM) [49]. However, similar to their results, when the IC50 values of Trp–Val and its reverse sequence were compared in the present study, the N-terminal Trp-containing dipeptides exhibited lower ACE-inhibitory activity than did the C-terminal-residue Trp-containing dipeptides, and the IC50 value increased from 0.58 to 307.61 μM. These results agree with the importance of amino acids at the C-terminal of dipeptides, as reported by Ono et al. [49]. Studies have reported that the ACE inhibition mode of peptides with Trp as the C-terminal residue—namely Val–Trp, Ile–Trp, and Leu–Trp—showed noncompetitive inhibition, whereas reversed sequence peptides with Trp at the N-terminal exhibited competitive inhibition [49,51]. In addition, Val–Trp, Ile–Trp, and Leu–Trp exhibited excellent ACE inhibition, which may have been because the carboxy terminals of these peptide sequences were all Trp-containing aromatic amino acids, whereas the nitrogen terminals were all branched-chain hydrophobic amino acids. This result is consistent with some previous studies [52]. Wu et al. [50] used Z descriptors to investigate the quantitative structure–activity relationship of 58 ACE dipeptides. They found that ACE inhibition was greatly affected by the three-dimensional chemical properties and hydrophobicity of C-terminal amino acids. Dipeptides with hydrophobic amino acids at the C-terminal, such as trypotophan, phenylalanine, and tyrosine, have stronger ACE-inhibitory activity. The identification results were consistent with the systematic induction results of Li et al. [53] and Cheung et al. [54] with respect to the properties of ACE-inhibitory peptides. In addition, Xiao et al. [55] further used flexible molecule docking technology to elucidate ACE active sites. The results demonstrated that hydrogen bonds; hydrophilic, hydrophobic, and electrostatic interactions; and coordinate bonds existed between the active pockets of the C-domain and Val–Trp and Ile–Trp. The interaction of the N-domain with the dipeptides was similar to that of the C-domain, which had fewer hydrogen bonds and no electrostatic interactions. However, further investigations regarding the relationship between the inhibitory mechanism and dipeptide structure are necessary.
Although these peptides have been reported in other foods, to date, no reports have revealed that these peptides arise from C. sorokiniana protein waste. Compared with salmon, Antarctic krill, and other foods that have been utilised to develop functional foods for the prevention of hypertension, C. sorokiniana protein waste is a cheap food source that can provide high additive value.

3.5. Antihypertensive Effect of C. sorokiniana Protein Hydrolysate

In short-term administration, C. sorokiniana protein hydrolysate (PN-1) containing 30 and 60 mg of peptide/rat BW (350 g; equivalent to 85.7 and 171.4 mg powder/kg BW) was administered to SHRs. Saline was used as a control that had negligible effects on SBP. SBP decreased significantly between 4 and 6 h after PN-1 administration and recovered to its initial level after 24 h. At 6 h after feeding, SBP reached its lowest point, namely 11.1 ± 2.8 mm Hg lower than that of the controls for the SHRs administered 30 mg/rat BW and 20.0 ± 3.2 mm Hg lower than that of the controls for the SHRs administered 60 mg/rat BW. A similar trend was observed for DBP, for which the values of the two experimental groups were 14.4 ± 5.3 and 21.0 ± 2.6 mm Hg lower than that of the controls, respectively (Figure 3). Other studies have examined the antihypertensive effects of ACE inhibitors on SHRs through short-term administration [56]. Upstream chum salmon (Oncorhynchus keta) muscle with thermolysin exhibited a potent antihypertensive effect in SHRs at 500 and 2000 mg of hydrolysate/kg BW at 4 h after oral administration, which resulted in decreases in SBP of 28 and 38 mm Hg, respectively. However, the main ACE-inhibitory peptides separated from the salmon hydrolysate were Val–Trp, Ile–Trp, and Leu–Trp. In addition, single oral administration of these three peptides (purified from brown seaweed—wakame) has been reported in detail by Sato et al. [41,51]. Results for Val–Trp, Ile–Trp, and Leu–Trp in SHRs revealed that a dose of 1 mg/kg BW exerted a blood pressure-lowering effect. Similar results revealed that a single dose of peptide fraction from C. vulgaris significantly reduced SBP to 49.9 mm Hg at 1 h, and the antihypertensive effect continued for 4 h after oral administration [21].

4. Conclusions

Residues of C. sorokiniana after hot water extraction were hydrolysed using Protease N 1% for 5 h. The IC50 of this hydrolysate (PN-1) to ACE was 0.035 mg/mL. PN-1 was administered to the SHRs through 30 and 60 mg of powder/350 g; after 6 h following oral administration, the SBPs of the two experimental groups were respectively 11.1 and 20.1 mm Hg lower than that of the control group, and the DBPs of the two experimental groups were 14.4 and 21.0 mmHg lower than that of the control group, respectively. Four inhibitory peptides were isolated from the hydrolysate that exhibited high ACE-inhibitory activity, and their amino acid sequences were Trp–Val, Val–Trp, Ile–Trp, and Leu–Trp, with IC50 values of 307.61, 0.58, 0.50, and 1.11 μM, respectively. These findings revealed ACE-inhibitory activity in vitro and antihypertensive activity in vivo. These findings suggest that an ACE inhibitor derived from C. sorokiniana protein hydrolysate could be utilised to develop functional foods for prevention of hypertension. In addition, this research provides evidence that small peptides from C. sorokiniana insoluble protein have potential for application because of their bioactivities.

Author Contributions

G.-W.C., J.-S.T., C.H.Y., and H.S. proposed and designed the experiment. G.-W.C. and Y.H.L. all participated in the experiment. Y.H.L., G.-W.C., and J.-S.T. analysed the data and composed the manuscript. G.-W.C. revised the manuscript and was responsible for supervising the research.

Funding

This research was funded by [the National Science Council, Taiwan, Republic of China] grant number [NSC98-2321-B-019-002].

Acknowledgments

This study was supported by Taiwan Chlorella Manufacturing Co., Ltd.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Sheih, I.C.; Fang, T.J.; Wu, T.K. Isolation and characterisation of a novel angiotensin I-converting enzyme (ACE) inhibitory peptide from the algae protein waste. Food Chem. 2009, 115, 279–284. [Google Scholar] [CrossRef]
  2. Wang, J.; Hu, J.; Cui, J.; Bai, X.; Du, A.Y.; Miyaguchi, Y.; Lin, B. Purification and identification of a ACE inhibitory peptide from oyster proteins hydrolysate and the antihypertensive effect of hydrolysate in spontaneously hypertensive rats. Food Chem. 2008, 111, 302–308. [Google Scholar] [CrossRef] [PubMed]
  3. Ondetti, M.A. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977, 196, 441–444. [Google Scholar] [CrossRef] [PubMed]
  4. Sawayama, T.; Itokawa, A.; Shimada, K.; Doi, Y.; Kimura, Y.; Nishimura, H. Synthesis of 1-[(S)-3-acetylthio-2-methylpropanoyl]-l-phenylalanine (Alacepril) and one of its active metabolites, the desacetyl derivative (DU-1227). Chem. Pharm. Bull. 1990, 38, 1767–1771. [Google Scholar] [CrossRef]
  5. Julius, S.; Nesbitt, S.D.; Egan, B.M.; Weber, M.A.; Michelson, E.L.; Kaciroti, N.; Black, H.R.; Grimm, R.H.; Messerli, F.H.; Oparil, S.; et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 2006, 354, 1685–1697. [Google Scholar] [CrossRef] [PubMed]
  6. Bhuyan, B.J.; Mugesh, G. Synthesis, characterization and antioxidant activity of angiotensin converting enzyme inhibitors. Org. Biomol. Chem. 2011, 9, 1356–1365. [Google Scholar] [CrossRef] [PubMed]
  7. Al Shohaib, S.; Raweily, E. Acute tubular necrosis due to captopril. Am. J. Nephrol. 2000, 20, 149–152. [Google Scholar] [CrossRef] [PubMed]
  8. Bhuyan, B.J.; Mugesh, G. Antioxidant activity of peptide-based angiotensin converting enzyme inhibitors. Org. Biomol. Chem. 2012, 10, 2237–2247. [Google Scholar] [CrossRef] [PubMed]
  9. Samarakoon, K.W.; O-Nam, K.; Ko, J.Y.; Lee, J.H.; Kang, M.C.; Kim, D.; Lee, J.B.; Lee, J.S.; Jeon, Y.J. Purification and identification of novel angiotensin-I converting enzyme (ACE) inhibitory peptides from cultured marine microalgae (Nannochloropsis oculata) protein hydrolysate. J. Appl. Phycol. 2013, 25, 1595–1606. [Google Scholar] [CrossRef]
  10. Yamada, A.; Sakurai, T.; Ochi, D.; Mitsuyama, E.; Yamauchi, K.; Abe, F. Novel angiotensin I-converting enzyme inhibitory peptide derived from bovine casein. Food Chem. 2013, 141, 3781–3789. [Google Scholar] [CrossRef] [PubMed]
  11. Pan, S.; Wang, S.; Jing, L.; Yao, D. Purification and characterisation of a novel angiotensin-I converting enzyme (ACE)-inhibitory peptide derived from the enzymatic hydrolysate of Enteromorpha clathrata protein. Food Chem. 2016, 211, 423–430. [Google Scholar] [CrossRef] [PubMed]
  12. Chen, G.W.; Tsai, J.S.; Sun, P.B. Purification of Angiotensin I-converting enzyme inhibitory peptides and antihypertensive effect of milk produced by protease-facilitated lactic fermentation. Int. Dairy J. 2007, 17, 641–647. [Google Scholar] [CrossRef]
  13. Chen, G.W.; Tsa, J.S.; Sun, P.B. Cardiovascular effects of whey from prozyme 6-facilitated lactic acid bacteria fermentation of milk. J. Food Biochem. 2007, 31, 639–655. [Google Scholar] [CrossRef]
  14. Tsai, J.S.; Chen, T.J.; Pan, B.S.; Gong, S.D.; Chung, M.Y. Antihypertensive effect of bioactive peptides produced by protease-facilitated lactic acid fermentation of milk. Food Chem. 2008, 106, 552–558. [Google Scholar] [CrossRef]
  15. Tsai, J.S.; Lin, T.C.; Chen, J.L.; Pan, B.S. The inhibitory effect of freshwater clam (Corbicula fluminea, Muller) muscle protein hydrolysates on angiotensin I converting enzyme. Process Biochem. 2006, 41, 2276–2281. [Google Scholar] [CrossRef]
  16. Tsai, J.S.; Chen, J.L.; Pan, B.S. ACE-inhibitory peptides identified from the muscle protein hydrolysate of hard clam (Meretrix lusoria). Process Biochem. 2008, 43, 743–747. [Google Scholar] [CrossRef]
  17. Terashima, M.; Baba, T.; Ikenmoto, N.; Katayama, M.; Morimoto, T.; Matsumura, S. Novel angiotensin-concerting enzyme (ACE) inhibitory peptides derived from boneless chicken leg meat. J. Agric. Food Chem. 2010, 58, 7432–7436. [Google Scholar] [CrossRef] [PubMed]
  18. Jang, J.H.; Jeong, S.C.; Kim, J.H.; Lee, Y.H.; Ju, Y.C.; Lee, J.S. Characterisation of a new antihypertensive angiotensin I-converting enzyme inhibitory peptide from Pleurotus cornucopiae. Food Chem. 2011, 127, 412–418. [Google Scholar] [CrossRef] [PubMed]
  19. Wijesekara, I.; Qian, Z.J.; Ryu, B.; Ngo, D.H.; Kim, S.K. Purification and identification of antihypertensive peptides from seaweed pipefish (Syngnathus schlegeli) muscle protein hydrolysate. Food Res Int. 2011, 44, 703–707. [Google Scholar] [CrossRef]
  20. Lin, H.C.; Alashi, A.M.; Aluko, R.E.; Sun, P.B.; Chang, Y.W. Antihypertensive properties of tilapia (Oreochromis spp.) frame and skin enzymatic protein hydrolysates. Food Nutr. Res. 2018, 61. Available online: https://www.tandfonline.com/doi/abs/10.1080/16546628.2017.1391666 (accessed on 20 August 2018). [CrossRef] [PubMed]
  21. Suetsuna, K.; Chen, J.R. Identification of antihypertensive peptides from peptic digest of two microalgae, Chlorella vulgaris and Spirulina platensis. Mar. Biotechnol. 2001, 3, 305–309. [Google Scholar] [CrossRef] [PubMed]
  22. Olivares-Molina, A.; Fernández, K. Comparison of different extraction techniques for obtaining extracts from brown seaweeds and their potential effects as angiotensin I-converting enzyme (ACE) inhibitors. J. Appl. Phycol. 2016, 28, 1295–1302. [Google Scholar] [CrossRef]
  23. Xie, J.; Chen, X.; Wu, J.; Zhang, Y.; Zhou, Y.; Zhang, L.; Tang, Y.J.; Wei, D. Antihypertensive effects, molecular docking study, and isothermal titration calorimetry assay of angiotensin I-converting enzyme inhibitory peptides from Chlorella vulgaris. J. Agric. Food Chem. 2018, 66, 1359–1368. [Google Scholar] [CrossRef] [PubMed]
  24. Okamoto, K.; Suzuki, T.; Ito, H.; Mitachi, Y.; Morita, N. Spontaneous Hypertension: Its Pathogenesis and Complications, 2nd ed.; DHEW Publication: Washington, WA, USA, 1976; pp. 1177–1179. [Google Scholar]
  25. Murakami, T.; Okamoto, K.; Ogaki, M.; Iizuka, Y. Effect of Chlorella on blood pressure, cerebral stroke lesions, hypertensive vascular change and life-span in spontaneously hypertensive rats. J. Jpn. Soc. Nutr. Food Sci. 1987, 40, 351–359. [Google Scholar] [CrossRef]
  26. Miyakoshi, M.; Tanaka, M.; Miyazawa, K.; Nara, H.; Takemoto, Y.; Maki, T.; Fukui, S.; Antoku, E.; Shinpo, K.; Shimizu, K. Study of Chlorella producted from the Chikugo area. Clin. Rep. 1980, 14, 3931–3941. [Google Scholar]
  27. Suetsuna, K. Purification and identification of angiotensin I–converting enzyme inhibitors from the red alga Porphyra yezoensis. J. Mar. Biotechnol. 1998, 6, 163–167. [Google Scholar] [PubMed]
  28. Suetsuna, K. Separation and identification of angiotensin I–converting enzyme inhibitory peptides from peptic digest of Hizikia fusiformis protein. Nippon Suisan Gakk. 1998, 64, 862–866. [Google Scholar] [CrossRef]
  29. Suetsuna, K.; Nakano, T. Identification of an antihypertensive peptide from peptic digest of wakame (Undaria pinnatifida). J. Nutr. Biochem. 2000, 11, 450–454. [Google Scholar] [CrossRef]
  30. Lu, J.; Ren, D.F.; Xue, U.L.; Sawano, Y.; Miyakawa, T.; Tanokura, M. Isolation of an antihypertensive peptide fome alcalase digest of Spirulina platensis. J. Agric. Food Chem. 2010, 58, 7166–7171. [Google Scholar] [CrossRef] [PubMed]
  31. Spolaore, P.; Joannis-Cassan, C.; Duran, E.; Isambert, A. Commercial applications of microalgae. J. Biosci. Bioeng. 2006, 101, 87–96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Lowry, O.H.; Resebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275. [Google Scholar] [PubMed]
  33. Cooper, T.G. Spectrophotometry. In The Tools of Biochemistry, 1st ed.; Wiley-Interscience: Hoboken, NJ, USA, 1977; pp. 53–55. ISBN 0471171166. [Google Scholar]
  34. Church, F.C.; Swaisgood, H.E.; Porter, H.D.; Catignani, G.L. Spectrophotometric assay using o-phthaldialdehyde for determination of proteolysis in milk and isolated milk proteins. J. Dairy Sci. 1983, 66, 1219–1227. [Google Scholar] [CrossRef]
  35. Cushman, D.W.; Cheung, H.S. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem. Parmacol. 1971, 20, 1637–1648. [Google Scholar] [CrossRef]
  36. Wu, J.; Ding, X. Characterization of inhibition and stability of soy-protein-derived angiotensin I-converting enzyme inhibitory peptides. Food Res. Int. 2002, 35, 367–375. [Google Scholar] [CrossRef]
  37. UniProt Database. Available online: http://www.uniprot.org (accessed on 15 May 2018).
  38. Pairwise Sequence Alignment Software. Available online: https://www.ebi.ac.uk/Tools/psa/ (accessed on 15 May 2018).
  39. SAS Institute Inc. SAS/STAT User’s Guide; SAS Institute Press: Cary, NC, USA, 1988; p. 584. [Google Scholar]
  40. Ruiz, J.Á.G.; Ramos, M.; Recio, J. Angiotensin converting enzyme inhibitory activity of peptides isolated from Manchego cheese. Stability under simulated gastrointestinal digestion. Int. Dairy J. 2004, 14, 1075–1080. [Google Scholar] [CrossRef]
  41. Sato, M.; Oba, T.; Yamaguchi, T.; Nakano, T.; Kahara, T.; Funayama, K.; Kobayashi, A.; Nakano, T. Antihypertensive effects of hydrolysates of wakame (Undar pinnatifida) and their angiotensin-I-converting enzyme inhibitory activity. Ann. Nutr. MeTab. 2002, 46, 259–267. [Google Scholar] [CrossRef] [PubMed]
  42. Sekiya, S.; Kobayashi, Y.; Kita, E.; Imamura, Y.; Toyama, S. Antihypertensive effects of tryptic hydrolysate of casein on normotensive and hypertensive volunteers. J. Jpn. Soc. Nutr. Food Sci. 1992, 45, 513–517. [Google Scholar] [CrossRef]
  43. Ben, H.Y.; Labidi, A.; Arnaudin, I.; Bridiau, N.; Delatouche, R.; Maugard, T.; Piot, J.M.; Sannier, F.; Thiéry, V.; Bordenave-Juchereau, S. Measuring angiotensin-I converting enzyme inhibitory activity by micro plate assays: Comparison using marine cryptides and tentative threshold determinations with captopril and losartan. J. Agric. Food Chem. 2013, 61, 10685–10690. [Google Scholar]
  44. Okamoto (Kainuma), A.; Matsumoto, E.; Iwashita, A.; Yasuhara, T.; Kawamura, Y.; Koizumi, Y.; Yanagida, F. Angiotensin I-converting enzyme inhibitory action of fish sauce. Food Sci. Technol. Int. 1995, 1, 101–106. [Google Scholar] [CrossRef]
  45. Saito, S.; Wanezaki (Nakamura), K.; Kawato, A.; Imayasu, S. Structure and activity of angiotensin I converting enzyme inhibitory peptides from sake and sake lees. Biosci. Biotechnol. Biochem. 1994, 58, 1767–1771. [Google Scholar] [CrossRef] [PubMed]
  46. Xu, Y.; Bao, T.; Han, W.; Zheng, X.; Wang, J. Purification and identification of an angiotensin I-converting enzyme inhibitory peptide from cauliflower byproducts protein hydrolysate. Process Biochem. 2016, 51, 1299–1305. [Google Scholar] [CrossRef]
  47. Fujita, H.; Yokoyama, K.; Yoshikawa, M. Classification and antihypertensive activity of angiotensin I-converting enzyme inhibitory peptides derived from food proteins. J. Food Sci. 2000, 65, 564–569. [Google Scholar]
  48. Martin, M.; Wellner, A.; Ossowski, I.; Henle, T. Identification and quantification of inhibitors for angiotensin-converting enzyme in hypoallergenic infant milk formulas. J. Agric. Food Chem. 2008, 56, 6333–6338. [Google Scholar] [CrossRef] [PubMed]
  49. Ono, S.; Hosokawa, M.; Miyashita, K.; Takahashi, K. Inhibition properties of dipeptides from salmon muscle hydrolysate on angiotensin I-converting enzyme. Int. J. Food Sci. Technol. 2006, 41, 383–386. [Google Scholar] [CrossRef]
  50. Wu, J.; Aluko, R.E.; Nakai, S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides:  Quantitative structure−activity relationship study of di- and tripeptides. J. Agric. Food Chem. 2006, 54, 732–738. [Google Scholar] [CrossRef] [PubMed]
  51. Sato, M.; Hosokawa, T.; Yamaguchi, T.; Nakano, T.; Muramoto, K.; Kahara, T.; Funayama, K.; Kobayashi, A.; Nakano, T. Angiotensin I-converting enzyme inhibitory peptides derived from wakame (Undaria pinnatifida) and their antihypertensive effect in spontaneously hypertensive rats. J. Agric. Food Chem. 2002, 50, 6245–6252. [Google Scholar] [CrossRef] [PubMed]
  52. He, R.; Ma, H.; Zhao, W.; Qu, W.; Zhao, J.; Luo, L.; Zhu, W. Modeling the QSAR of ACE-inhibitory peptides with ANN and its applied illustration. Int. J. Pept. 2012. [Google Scholar] [CrossRef] [PubMed]
  53. Li, G.H.; Le, G.W.; Shi, Y.H.; Shrestha, S. Angiotensin-I-converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. Nutr. Res. 2004, 24, 469–486. [Google Scholar] [CrossRef]
  54. Cheung, H.S.; Wang, F.L.; Ondetti, M.A.; Sabo, E.F.; Cushman, D.W. Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. J. Biol. Chem. 1980, 255, 401–407. [Google Scholar] [PubMed]
  55. Xiao, G.; Yanhan, H.; Jing, L.; Jing, L.; Zhu, S.; Fei, H. Binding modes between C-domain selective angiotensin-converting enzyme (ACE) inhibitory dipeptides and ACE domains. Food Sci. 2017, 38, 160–166. [Google Scholar] [CrossRef]
  56. Ono, S.; Hosokawa, M.; Miyashita, K.; Takahashi, K. Isolation of peptides with angiotensin I-converting enzyme inhibitory effect derived from hydrolysate of upstream chum salmon muscle. J. Food Sci. 2003, 68, 1611–1614. [Google Scholar] [CrossRef]
Nutrients 10 01397 g001 550
Figure 1. Sephadex G-15 column chromatography of peptides separated from PN-1 after digestion by gastrointestinal proteases. ● Standard materials: bacitracin (1422 Da); penta-L-phenylalanine (753.9 Da); and L-tryptophan (204.2 Da).
Figure 1. Sephadex G-15 column chromatography of peptides separated from PN-1 after digestion by gastrointestinal proteases. ● Standard materials: bacitracin (1422 Da); penta-L-phenylalanine (753.9 Da); and L-tryptophan (204.2 Da).
Nutrients 10 01397 g001
Nutrients 10 01397 g002 550
Figure 2. Elution profile of fraction F from Figure 1 by reversed phase-high performance liquid chromatography (RP-HPLC). Column: Synergi 4u Hydro-RP 80A (10 × 250 mm2; particle size: 4 μm; Phenomenex); elution A (deionised water containing 0.1% trifluoroacetic acid) and B (100% acetonitrile containing 0.1% trifluoroacetic acid); mobile phase: a linear gradient from 0% to 40% of B within 120 min; flow rate of 1.5 mL/min at room temperature, and detection at 220 nm.
Figure 2. Elution profile of fraction F from Figure 1 by reversed phase-high performance liquid chromatography (RP-HPLC). Column: Synergi 4u Hydro-RP 80A (10 × 250 mm2; particle size: 4 μm; Phenomenex); elution A (deionised water containing 0.1% trifluoroacetic acid) and B (100% acetonitrile containing 0.1% trifluoroacetic acid); mobile phase: a linear gradient from 0% to 40% of B within 120 min; flow rate of 1.5 mL/min at room temperature, and detection at 220 nm.
Nutrients 10 01397 g002
Nutrients 10 01397 g003 550
Figure 3. Changes in blood pressure of SHRs after oral administration of PN-1. (a) SBP; (b) DBP. —O—, 0.9% NaCl in water as control; —●—, 30 mg of C. sorokiniana protein hydrolysate powder with 0.9% NaCl; —▲—, 60 mg of C. sorokiniana protein hydrolysate powder with 0.9% NaCl. Each point represents a mean value (n = 6) and the vertical bars represent the standard errors. *: significant difference from the control, p < 0.05.
Figure 3. Changes in blood pressure of SHRs after oral administration of PN-1. (a) SBP; (b) DBP. —O—, 0.9% NaCl in water as control; —●—, 30 mg of C. sorokiniana protein hydrolysate powder with 0.9% NaCl; —▲—, 60 mg of C. sorokiniana protein hydrolysate powder with 0.9% NaCl. Each point represents a mean value (n = 6) and the vertical bars represent the standard errors. *: significant difference from the control, p < 0.05.
Nutrients 10 01397 g003
Table
Table 1. Effect of treatment on soluble protein and peptide content, yield, and angiotensin I-converting enzyme (ACE) IC50 of C. sorokiniana protein hydrolysates.
Table 1. Effect of treatment on soluble protein and peptide content, yield, and angiotensin I-converting enzyme (ACE) IC50 of C. sorokiniana protein hydrolysates.
SampleSoluble Protein (mg/g)Peptide Content (mg/g)Yield 1IC50 2 (mg/mL)
HWE 3379.9 ± 1.5179.7 ± 2.14.01.070 ± 0.020
PX-1 4482.0 ± 2.2260.4 ± 2.019.10.043 ± 0.001
PX-2 5566.6 ± 3.5298.6 ± 2.022.70.043 ± 0.002
PN-1 6574.8 ± 2.3332.8 ± 3.028.10.035 ± 0.002
PN-2 7610.6 ± 3.8341.6 ± 3.131.20.042 ± 0.001
Each value represents the average of three samples. 1 Yield: (1-dry weight of sample after treatment/dry weight of sample) × 100%. 2 The concentration of an inhibitor required to inhibit 50% of ACE activity. 3 HWE: the hot water extract of C. sorokiniana. 4 PX-1: hydrolysate from Protamex hydrolysis at 1% (the enzyme-to-protein ratio was 1: 100 w/w) for 5 h. 5 PX-2: hydrolysate from Protamex hydrolysis at 2% (the enzyme-to-protein ratio was 2:100 w/w) for 5 h. 6 PN-1: hydrolysate from protease N hydrolysis at 1% (the enzyme-to-protein ratio was 1:100 w/w) for 5 h. 7 PN-2: hydrolysate from protease N hydrolysis at 2% (the enzyme-to-protein ratio was 2:100 w/w) for 5 h.
Table
Table 2. Effect of gastrointestinal protease hydrolysis on ACE-inhibitory activity of PN-1.
Table 2. Effect of gastrointestinal protease hydrolysis on ACE-inhibitory activity of PN-1.
ProteaseIC50 (mg Peptide/mL)
Control0.035 ± 0.002
Pepsin 10.044 ± 0.001
Pepsin + Pancreatin 20.044 ± 0.001
Each value represents the average of three samples. 1 Hydrolysed for 4 h. 2 Pepsin hydrolysed for 4 h followed by pancreatin hydrolysed for 4 h.
Table
Table 3. ACE IC50 of the size exclusion chromatographic fractions obtained from PN-1 after digestion by gastrointestinal proteases.
Table 3. ACE IC50 of the size exclusion chromatographic fractions obtained from PN-1 after digestion by gastrointestinal proteases.
FractionMolecular Weight (Da)Inhibition (%)Peptide Content (mg/mL)IER 1 (%/mg/mL)IC50 (mg/mL)
A1400–118074.00.210350— 2
B1180–91030.60.02711300.0450
C910–74058.20.02522300.0187
D680–59048.00.064750—
E460–37073.20.05712800.0160
F340–27068.60.03420200.0150
G200–25040.00.053760—
Each value represents the average of three samples. 1 IER: inhibitory efficiency ratio = % inhibition/peptide content. 2 Undetected.
Table
Table 4. ACE IER of peaks isolated from fraction F of PN-1G.
Table 4. ACE IER of peaks isolated from fraction F of PN-1G.
PeakACE Inhibitory (%)Peptide Content (mg/mL)IER (%/mg/mL)
F114.30.011430
F219.10.011910
F341.20.022060
F436.80.013680
F572.40.023621
F675.70.032523
F754.30.015425
F886.10.018613
F995.10.019510
F1087.70.018770
Each value represents the average of three samples. IER: inhibitory efficiency ratio = % inhibition/peptide content.
Table
Table 5. Peptide sequences and IC50 of various peaks (F7 to F10) from PN-1G.
Table 5. Peptide sequences and IC50 of various peaks (F7 to F10) from PN-1G.
PeakSequenceIC50 (μM)
F7Trp–Val307.61 ± 0.01
F8Val–Trp0.58 ± 0.02
F9Ile–Trp0.50 ± 0.01
F10Leu–Trp1.11 ± 0.02

Share and Cite

MDPI and ACS Style

Lin, Y.-H.; Chen, G.-W.; Yeh, C.H.; Song, H.; Tsai, J.-S. Purification and Identification of Angiotensin I-Converting Enzyme Inhibitory Peptides and the Antihypertensive Effect of Chlorella sorokiniana Protein Hydrolysates. Nutrients 2018, 10, 1397. https://doi.org/10.3390/nu10101397

AMA Style

Lin Y-H, Chen G-W, Yeh CH, Song H, Tsai J-S. Purification and Identification of Angiotensin I-Converting Enzyme Inhibitory Peptides and the Antihypertensive Effect of Chlorella sorokiniana Protein Hydrolysates. Nutrients. 2018; 10(10):1397. https://doi.org/10.3390/nu10101397

Chicago/Turabian Style

Lin, Yu-Hsin, Guan-Wen Chen, Chin Hsi Yeh, Helena Song, and Jenn-Shou Tsai. 2018. "Purification and Identification of Angiotensin I-Converting Enzyme Inhibitory Peptides and the Antihypertensive Effect of Chlorella sorokiniana Protein Hydrolysates" Nutrients 10, no. 10: 1397. https://doi.org/10.3390/nu10101397

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop